Carbometyx
Ipsen’s cabozantinib accepted by SMC for adults with advanced neuroendocrine tumours
NETs affect approximately seven per 100,000 people in Scotland
Ipsen to acquire Memo Therapeutics in deal worth more than €700m
The deal expands the company’s rare disease portfolio
Ipsen appoints Michelle Werner as Executive Vice President, President of North America
Werner previously held senior roles at Bristol Myers Squibb, AstraZeneca and Novartis
BMS’ Opdivo gets expanded FDA and EU approval for Hodgkin lymphoma
This type of cancer is the most common one diagnosed in teenagers
Ipsen appoints Pierrick Lefranc as Executive Vice President Technical Operations
Lefranc has served at Ipsen since 2013, most recently as Senior Vice President
Ipsen to acquire ImCheck Therapeutics in a deal worth up to €1bn
The acquisition includes a clinical stage acute myeloid leukaemia treatment currently in phase 1/2 trials
Ipsen’s tumour treatment receives MHRA marketing authorisation
This is the first approval in the UK for previously treated advanced neuroendocrine tumours
Ipsen receives EC approval for Cabometyx in advanced neuroendocrine tumours
Treatment options following disease progression have previously been limited for many patients
Ipsen receives CHMP recommendation for Cabometyx in neuroendocrine tumours
The number of patients newly diagnosed with NETs is believed to be on the rise
GSK’s Blenrep combination recommended by NICE to treat multiple myeloma
The decision means that eligible patients in England will be the first in the world to access the combination
Bristol Myers Squibb’s perioperative Opdivo regimen granted EC approval in NSCLC
Up to 55% of patients with non-metastatic NSCLC develop recurrence despite curative resection
Bristol Myers Squibb’s injectable Opdivo formulation granted MHRA for solid tumours
The new formulation reduces administration time from 30-to-60 minutes to three-to-five minutes